Anti-infective treatment of purulent meningitis caused by carbapenem-resistant Klebsiella pneumoniae in a newborn: a case report
Abstract
The widespread use of carbapenems has caused a notable spread of carbapenem-resistant Klebsiella pneumoniae (CRKP). The incidence of CRKP-associated infections is rising significantly in neonatal intensive care units (NICUs), which poses a grave challenge to clinical treatment. This paper is to highlight the drug treatment of CRKP with purulent meningitis in children and explore the safety of levofloxacin in children. We retrospectively analyzed the clinical data of combination therapy with levofloxacin and aztreonam in a newborn with purulent meningitis caused by CRKP. As clinical pharmacists, we evaluated the risks and benefits of quinolones for anti-infective treatment in newborns, helped clinicians adjust the anti-infective protocol of levofloxacin combined with aztreonam and provided pharmaceutical care throughout the course of treatment. In the end, the child had no fever, no dyspnea, and no obvious abnormalities in brain color Doppler ultrasound. The intracranial infection was finally controlled, and the child improved and was discharged, with no apparent neurological, skeletal, joint, tendon, or cardiac adverse events. For newborns with CRKP-associated purulent meningitis, fluoroquinolones combined with other drugs such as polymyxin, tigecycline, aminoglycosides, minocycline, that Klebsiella pneumoniae is susceptible to (when no safe and effective anti-infective alternatives are available) can reduce the mortality rate of newborns with purulent meningitis caused by…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Ferulic acid regulates the AKT/GSK-3β/CRMP-2 signaling pathway in a middle cerebral artery occlusion animal model
- Novel Pharmacokinetic/Pharmacodynamic Parameters Quantify the Exposure–Effect Relationship of Levofloxacin against Fluoroquinolone-Resistant Escherichia coli
- Photochemical behavior of levofloxacin
- Correlation Between Dissolution Profiles of Salt-Form Drugs in Biorelevant Bicarbonate Buffer and Oral Drug Absorption: Importance of Dose/ Fluid Volume Ratio
- Evaluation of the synergistic potential and mechanisms of action for de novo designed cationic antimicrobial peptides
- Synthesis of [11C]levofloxacin
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.